// App-Quantinova.ai

4406 : ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle cell lymphoma in-vitro and in-vivo

Researchers

Presenter

  • Rajeswaran Mani

Principal Investigators

  • Chi-Ling Chiang

  • Frank W. Frissora

  • Robert Baiocchi

  • L. James Lee

  • Natarajan Muthusamy

  • Ribai Yan

  • Xiaokui Mo

  • Sivasubramanian Baskar

  • Christoph Rader

  • Mitch Phelps

  • Ching-Shih Chen

  • Robert Lee

  • John Byrd

Medical Centers

  • The Scripps Research Institute, Jupiter, FL

  • Center of Cancer Research, Bethesda, MD

  • The Ohio State Univerisity, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Acute lymphoblastic leukemia

  • Non-Hodgkin's Lymphoma

  • Mantle cell lymphoma

  • B cell lymphomas

  • Hodgkin's Lymphoma

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Hepatocyte growth factor receptor

Drug/Treatment

  • milatuzumab

  • Fingolimod

  • L-Tyrosine

  • FTY720

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved